[Pulmonary hemorrhage after abciximab. Risk factors and the role of protamine].
Large clinical trials have demonstrated the clinical effectiveness of therapy with inhibitors of the platelet surface-membrane glycoprotein IIb-IIIa receptor in a broad range of patients with ischemic heart disease. Abciximab, a platelet glycoprotein IIb-IIIa receptor blocker, is associated with improved long-term prognosis in patients who require angioplasty and stent placement. Severe bleeding from abciximab use is an uncommon event. We describe a patient with severe pulmonary hemorrhage after treatment with abciximab, and discuss predisposing factors and protamine infusion in this potentially fatal complication.
Rodríguez-Gómez
Francisco J
FJ
Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, España. med007369@saludalia.com
Sánchez
Angel
A
Martínez
Francisco J
FJ
Andreu
Juan
J
Alvarez
Alejandra
A
Pujol
Emilio
E
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011479:Protamines / Q000627:therapeutic use*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011479:Protamines; D000077284:Abciximab